The clinical use of DNA methyltransferase inhibitors in myelodysplastic syndromes

被引：29

作者：

Abou Zahr, Abdallah ^{[1
]}

Aldin, Ehab Saad ^{[2
]}

Barbarotta, Lisa ^{[3
]}

Podoltsev, Nikolai ^{[3
]}

Zeidan, Amer M. ^{[3
]}

机构：

[1] Mt Sinai Beth Israel, Div Hematol Oncol, New York, NY USA

[2] Univ Iowa Hosp & Clin, Dept Diagnost Radiol, Iowa City, IA 52242 USA

[3] Yale Univ, Div Hematol, Dept Med, New Haven, CT 06520 USA

来源：

EXPERT REVIEW OF ANTICANCER THERAPY | 2015年 / 15卷 / 09期

关键词：

allogeneic hematopoietic stem cell transplant; azacitidine; azanucleosides; decitabine; DNA methyltransferase inhibitors; epigenetics; hypomethylating agents; myelodysplastic syndromes; ACUTE MYELOID-LEUKEMIA; STEM-CELL TRANSPLANTATION; DONOR LYMPHOCYTE INFUSIONS; CONVENTIONAL CARE REGIMENS; PROGNOSTIC SCORING SYSTEM; CHRONIC MYELOMONOCYTIC LEUKEMIA; RANDOMIZED CONTROLLED-TRIAL; ACUTE MYELOGENOUS LEUKEMIA; WORLD-HEALTH-ORGANIZATION; LOW-DOSE AZACITIDINE;

D O I：

10.1586/14737140.2015.1061936

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Myelodysplastic syndromes (MDS) include a heterogeneous group of acquired hematopoietic malignancies characterized by ineffective hematopoiesis, peripheral cytopenias, and a varying propensity for progression to acute myeloid leukemia. Patients with higher risk MDS have dismal outcomes and treatment options are very limited. Aside from allogeneic hematopoietic cell transplantation, the only potentially curative treatment, DNA methyltransferase inhibitors (DNMTIs) are the only intervention that prolongs overall survival in patients with higher risk MDS. The clinical use of DNMTIs in MDS was one of the earliest successful attempts at epigenetic reprogramming of cancer. In this review, we discuss the clinical use of DNMTIs in MDS highlighting the current challenges and controversies and future directions of research needed to explore the full therapeutic potential of these agents.

引用

页码：1019 / 1036

页数：18

共 169 条

[1] Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies [J].

Abdel-Wahab, Omar ;

Mullally, Ann ;

Hedvat, Cyrus ;

Garcia-Manero, Guillermo ;

Patel, Jay ;

Wadleigh, Martha ;

Malinge, Sebastien ;

Yao, JinJuan ;

Kilpivaara, Outi ;

Bhat, Rukhmi ;

Huberman, Kety ;

Thomas, Sabrena ;

Dolgalev, Igor ;

Heguy, Adriana ;

Paietta, Elisabeth ;

Le Beau, Michelle M. ;

Beran, Miloslav ;

Tallman, Martin S. ;

Ebert, Benjamin L. ;

Kantarjian, Hagop M. ;

Stone, Richard M. ;

Gilliland, D. Gary ;

Crispino, John D. ;

Levine, Ross L. .

BLOOD, 2009, 114 (01) :144-147

[2] RNA-dependent inhibition of ribonucleotide reductase is a major pathway for 5-azacytidine activity in acute myeloid leukemia [J].

Aimiuwu, Josephine ;

Wang, Hongyan ;

Chen, Ping ;

Xie, Zhiliang ;

Wang, Jiang ;

Liu, Shujun ;

Klisovic, Rebecca ;

Mims, Alice ;

Blum, William ;

Marcucci, Guido ;

Chan, Kenneth K. .

BLOOD, 2012, 119 (22) :5229-5238

[3] The DNA demethylating agent 5-aza-2′-deoxycytidine induces expression of NY-ESO-1 and other cancer/testis antigens in myeloid leukemia cells [J].

Almstedt, Maika ;

Blagitko-Dorfs, Nadja ;

Duque-Afonso, Jesus ;

Karbach, Julia ;

Pfeifer, Dietmar ;

Jaeger, Elke ;

Luebbert, Michael .

LEUKEMIA RESEARCH, 2010, 34 (07) :899-905

[4]

[Anonymous], BLOOD

[5]

Batty GN, CLIN LYMPHOMA MYELOM, V10, P10

[6] TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients [J].

Bejar, Rafael ;

Lord, Allegra ;

Stevenson, Kristen ;

Bar-Natan, Michal ;

Perez-Ladaga, Albert ;

Zaneveld, Jacques ;

Wang, Hui ;

Caughey, Bennett ;

Stojanov, Petar ;

Getz, Gad ;

Garcia-Manero, Guillermo ;

Kantarjian, Hagop ;

Chen, Rui ;

Stone, Richard M. ;

Neuberg, Donna ;

Steensma, David P. ;

Ebert, Benjamin L. .

BLOOD, 2014, 124 (17) :2705-2712

[7] Validation of a Prognostic Model and the Impact of Mutations in Patients With Lower-Risk Myelodysplastic Syndromes [J].

Bejar, Rafael ;

Stevenson, Kristen E. ;

Caughey, Bennett A. ;

Abdel-Wahab, Omar ;

Steensma, David P. ;

Galili, Naomi ;

Raza, Azra ;

Kantarjian, Hagop ;

Levine, Ross L. ;

Neuberg, Donna ;

Garcia-Manero, Guillermo ;

Ebert, Benjamin L. .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (27) :3376-3382

[8] Myeloid-specific inactivation of p15Ink4b results in monocytosis and predisposition to myeloid leukemia [J].

Bies, Juraj ;

Sramko, Marek ;

Fares, Joanna ;

Rosu-Myles, Michael ;

Zhang, Steven ;

Koller, Richard ;

Wolff, Linda .

BLOOD, 2010, 116 (06) :979-987

[9] 5-Azacytidine as Salvage Treatment in Relapsed Myeloid Tumors after Allogeneic Bone Marrow Transplantation [J].

Bolanos-Meade, Javier ;

Smith, B. Douglas ;

Gore, Steven D. ;

McDevitt, Michael A. ;

Luznik, Leo ;

Fuchs, Ephraim J. ;

Jones, Richard J. .

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2011, 17 (05) :754-758

[10] Activity of decitabine in patients with myelodysplastic syndrome previously treated with azacitidine [J].

Borthakur, Gautam ;

El Ahdab, Samih ;

Ravandi, Farhad ;

Faderl, Stefan ;

Ferrajoli, Alessandra ;

Newman, Beth ;

Issa, Jean-Pierre ;

Kantarjian, Hagop .

LEUKEMIA & LYMPHOMA, 2008, 49 (04) :690-695

← 1 2 3 4 5 6 7 8 9 10 →